臺北醫學大學國際生醫工程博士學位學程（IPBME）的Lucas A. Lane助理教授，與臺北醫學大學醫學院放射線學科/臺北醫學大學附設醫院放射腫瘤科的李欣倫教授榮獲2026年德國ImmunoTools公司的「FlowISiAM Award」研究獎。
他們獲獎的研究計畫名稱為「鑑定兒童神經母細胞瘤單核細胞衍生之生物標記的早期偵測、質子治療預後和分層治療」（Identification of Monocyte-Derived Biomarkers for Early Detection, Proton Therapy Prognosis, and Treatment Stratification in Childhood Neuroblastoma）。此計畫專注於兒童神經母細胞瘤，並利用FlowISiAM（利用流式細胞儀在活化的單核細胞或巨噬細胞內染色）平臺來研究週邊血液中單核細胞和巨噬細胞衍生的生物標記，該研究旨在開發一種以血液為基礎的生物標記微創技術，用於早期偵測、監測質子治療期間的反應和預後，以及對神經母細胞瘤進行生物風險分層。【上圖：左起Lucas A. Lane教授、李欣倫教授】
該計畫結合Prof. Lane在奈米醫學、癌症診斷和腫瘤相關巨噬細胞生物學方面的專業知識，以及李欣倫教授在放射腫瘤學和質子治療方面的臨床專業知識，該研究也將與德國ImmunoTools GmbH公司及其合作夥伴INVIGATE生技公司偕同進行，以推展 FlowISiAM 技術在兒科腫瘤精準醫療的應用。（文/醫學工程學院）
Congratulations to Dr. Lucas A. Lane on Receiving the ImmunoTools FlowISiAM Award 2026
Congratulations to Prof. Lucas A. Lane of the International Ph.D. Program in Biomedical Engineering (IPBME), Taipei Medical University, and Prof. Hsin-Lun Lee of the Department of Radiology, School of Medicine, and Division of Radiation Oncology, Taipei Medical University Hospital, on receiving the ImmunoTools FlowISiAM Award 2026.
Their awarded research project is entitled：“Identification of Monocyte-Derived Biomarkers for Early Detection, Proton Therapy Prognosis, and Treatment Stratification in Childhood Neuroblastoma”The project focuses on childhood neuroblastoma and will utilize the FlowISiAM (Flow cytometry-based Intracellular Staining in Activated Monocytes or Macrophages) platform to investigate monocyte- and macrophage-derived biomarkers in peripheral blood. The study aims to develop a minimally invasive blood-based biomarker approach for early detection, monitoring treatment response and prognosis during proton therapy, and biological risk stratification of neuroblastoma.
The project brings together Prof. Lane’s expertise in nanomedicine, cancer diagnostics, and tumor-associated macrophage biology and Prof. Lee’s clinical expertise in radiation oncology and proton therapy. The research will also be conducted in collaboration with ImmunoTools GmbH and its partner INVIGATE in Germany to advance the application of FlowISiAM technology in precision medicine for pediatric oncology.
